PTPH1 Dephosphorylatesates and Cooperates with p38y MAPK to Increase Ras Oncogenesis through PDZ-Mediated Interaction

Cancer Research

Volumn 70, Issue 7, 2010, Pages 2901-2910

  Hou, Song Wang ^a   Zhi, Hui Ying ^a   Pohl, Nicole ^a   Loesch, Mathew ^a   Qi, Xiao Mei ^a   Li, Rong Shan ^b   Basir, Zainab ^b   Chen, Guan ^a,b  

^a Zablocki Veterans Affairs Medical Center   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE 12; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 3; PDZ PROTEIN; PTPN3 PROTEIN, HUMAN; RAS PROTEIN; SMALL INTERFERING RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CARCINOGENESIS; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; MOUSE; NONHUMAN; ONCOGENE RAS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; BIOSYNTHESIS; CELL GROWTH; CELL STRAIN HCT116; CELL TRANSFORMATION; COLON TUMOR; ENZYMOLOGY; GENETICS; METABOLISM; PATHOLOGY; PDZ DOMAIN; PHOSPHORYLATION; PHYSIOLOGY; PROTEIN DOMAIN; SIGNAL TRANSDUCTION;

CELL GROWTH PROCESSES; CELL TRANSFORMATION, NEOPLASTIC; COLONIC NEOPLASMS; GENES, RAS; HCT116 CELLS; HUMANS; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE 12; PDZ DOMAINS; PHOSPHORYLATION; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 3; RAS PROTEINS; RNA, SMALL INTERFERING;

EID: 77950794747     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-3229     Document Type: Article

References (31)

1. Downward J. Targeting Ras signalling pathways in cancer therapy. Nat Rev Cancer 2003;3:11-22.
2. Han J, Sun P. The pathways to tumor supression via route p38. Trends Biochem Sci 2007;32:364-371
3. Loesch M, Chen G. The p38 MAPK stress pathway as a tumor suppressor or more? Front Biosei 2008;13:3581-3593
4. Chen G, Hitomi M, Han J, Stacey DW. The p38 pathway provides negative feedback to Ras proliferative signaling. J Biol Chem 2000; 275:38973-38980
5. Qi X, Tang J, Pramanik R, et al. p38 MAPK activation selectively induces cell death in K-ras mutated human colon cancer cells through regulation of vitamin D receptor. J Biol Chem 2004;279:22138-22144
6. Brancho D, Tanaka N, Jaeschke A, et al. Mechanism of p38 MAP kinase activation in vivo. Genes Dev 2003;17:1969-1978
7. Dolado I, Swat A, Ajenjo N, De Vita G, Cuadrado A, Nebreda AR. p38α MAP kinase as a sensor of reactive oxygen species in tumorigenesis. Cancer Cell 2007;11:191-205.
8. Sun P, Yoshizuka N, New L, et al. PRAK is essential for ras-indueed senescence and tumor suppression. Cell 2007;128:295-308.
9. Tang J, Qi X, Mercola D, Han J, Chen G. Essential role of p38y in K-Ras transformation independent of phosphorylation. J Biol Chem 2005;280:23910-23917
10. Qi X, Tang J, Loesch M, Pohl N, Alkan S, Chen G. p38y MAPK integrates signaling cross-talk between Ras and estrogen receptor to increase breast cancer invasion. Cancer Res 2006;66:7540-7547
11. Qi X, Pohl NM, Loesch M, et al. p38aα antagonizes p38γ activity through c-Jun-dependent ubiquitin-proteasome pathways in regulating Ras transformation and stress response. J Biol Chem 2007; 282:31398-31408
12. Hasegawa M, Cuenda A, Spillartini MG, et al. Stress-activated protein kinase-3 interacts with the PDZ domain of a1-syntrophin: a mechanism for specific substrate recognition. J Biol Chem 1999; 274:12626-12631
13. Sabio G, Reuver S, Feijoo C, et al. Stress- and mitogen-induced phosphorylation of the synapse-associated protein SAP90/PSD-95 by activation of SAPK3/p38y and ERK1/ERK2. Biochem J 2004; 380:19-30.
14. Sabio G, Simon J, Arthur C, et al. p38yγ regulates the localisation of SAP97 in the cytoskeleton by modulating its interaction with GKAP. EMBO J 2005;24:1134-1145
15. 15. Cuenda A, Cohen P. Stress-activated protein kinase-2/p38 and a rapamycin-sensitive pathway are required for C2C12 myogenesis. J Biol Chem 1999;274:4341-4346 (Pubitemid 129503080)
16. Zhi H, Yang XJ, Kuhnmuench J, et al. SmgGDS is up-regulated in prostate carcinoma and promotes tumour phenotypes in prostate cancer cells. J Pathol 2009;217:389-397
17. Nagata Y, Lan K-H, Zhou X, et al. PTEN actiation, contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004;6:117-127
18. Yang Q, Tonks NK. Isolation of a cDNA clone encoding a human protein-tyrosine phosphatase with homology to the cytoskeletalassociated proteins band 4.1, ezrin, and talin. Proc Natl Acad Sci U S A 1991;88:5949-5953
19. Zhang S-H, Liu J, Kabayashi R, Tonks NK. Identification of the cell cycle regulator VCP (p97/CDC48) as a substrate of the band 4.1related protein-tyrosine phosphatase PTPH1. J Biol Chem 1999; 274:17806-17812
20. Sozio MS, Mathis MA, Young JA, et al. PTPH1 is a predominant protein-tyrosine phosphatase capable of interacting with and dephosphorylating the T cell receptor & subunit. J Biol Chem 2004;279: 7760-7769
21. Flint AJ, Tiganis T, Barford D, Tonks NK. Development of "substratetrapping" mutants to identify physiological substrates of protein tyrosine phosphatases. Proe Natl Acad Sci U S A 1997;94: 1680-1685
22. 22. Tiganis T, Bennett AM. Protein tyrosine phosphatase function: the substrate perspective. Biochem J 2007;402:1-15. (Pubitemid 46254902)
23. Barr AJ, Knapp S. MAPK-specific tyrosine phosphatases: new targets for drug discovery? Trends Pharmacol Sci 2006;27:525-530
24. Nagahara H, Vocero-Akbani AM, Snyder EL, et al. Transduction of full-length TAT fusion proteins into mammalian cells: TAT-p27kip1 induces cell migration. Nat Med 1998;4:1449-1452
25. Wang Z, Shen D, Parsons DW, et al. Mutational analysis of the tyrosine phosphatome in colorectal cancers. Science 2004;304:1164-1166
26. Raman M, Chen W, Cobb MH. Differential regulation and properties of MAPKs. Oncogene 2007;26:3100-3112
27. Owens DM, Keyse SM. Differential regulation of MAP kinase signaling by dual-specificity protein phosphatases. Oncogene 2007;26: 3203-3213
28. Tonks NK. Protein tyrosine phosphatases: from genes, to function, to disease. Nat Rev Mol Cell Biol 2006;7:833-846
29. Tartaglia M, Niemeyer CM, Fragale A, et al. Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nat Genet 2003;34:148-150
30. Saxena M, Williams S, Tasken K, Mustelin T. Crosstalk between cAMP-dependent kinase and MAP kinase through a protein tyrosine phosphatase. Nat Cell Biol 1999;1:305-311
31. Julien SG, Dube N, Read M, et al. Protein tyrosine phosphatase 1B deficiency or inhibition delays ErB2-induced mammary tumorigenesis and protects from lung metastasis. Nat Gen 2007;39:338-346